Evicenter
MarkdownMedical informationP&T meetings
Ivonescimab

EGFR-mutated non-small-cell lung cancer

Launch
Not announced
Last updated
73 sources

Section 4 of 6

Clinical evidence

157 evidence topics · 29 sources

Study summaries

HARMONi

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
HARMONi: primary overall survival analysis, median survival
Health-related quality of life and patient-reported outcomes
Safety results
Summary

The sponsor table retains randomized arm sizes of 219. The primary publication reports safety denominators of 218 treated participants per arm.

Study limitations
Summary

The primary PFS analysis included 345 participants, not all 438 randomized participants. The primary OS comparison did not meet its significance boundary. The later HR of 0.76 is a follow-up result and does not replace the primary OS test. Intracranial findings were exploratory and outside the multiplicity-controlled hierarchy. Because the analysis included third-generation TKI-treated participants from HARMONi-A, the two trials should not be pooled as independent populations. The comparator was chemotherapy alone, not another active post-TKI combination.

HARMONi-A

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using IRRC-assessed progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
HARMONi-A: enrollment
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
HARMONi-A: initial progression-free survival
Evidence elementDirect quotation
Median progression-free survival, ivonescimab plus chemotherapy, months“7.1 (95% CI, 5.9-8.7)”View highlighted excerpt for this quote
Median progression-free survival, placebo plus chemotherapy, months“4.8 (95% CI, 4.2-5.6)”View highlighted excerpt for this quote
Progression-free survival comparison“hazard ratio [HR], 0.46 [95% CI, 0.34-0.62]; P < .001”View highlighted excerpt for this quote
HARMONi-A: final overall survival
Evidence elementDirect quotation
Median overall survival, ivonescimab plus chemotherapy versus placebo plus chemotherapy“16.8 months vs 14.1 months”View highlighted excerpt for this quote
Overall survival comparison“hazard ratio, 0.74; 95% CI, 0.58-0.95; P = .02”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

All 322 participants were enrolled at sites in China, which limits direct geographic generalization. The initial publication reported PFS; the subsequent final OS publication should be considered separately rather than treating early survival immaturity as a continuing limitation. The final OS comparison favored ivonescimab, but grade 3 or higher TEAEs were reported in 67.1% versus 54.7%. HARMONi incorporates an overlapping third-generation TKI-treated population, so its findings are not wholly independent replication.

AK112-201

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using objective response rate as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Phase II study: EGFR-mutated cohort efficacy
Evidence elementDirect quotation
Objective response rate, cohort 2“68.4% (13/19) [95% CI, 43.4-87.4]”View highlighted excerpt for this quote
Median progression-free survival, cohort 2, months“8.5 [95% CI, 5.5-NE]”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The EGFR-mutated cohort contained 19 participants in an open-label study without a concurrent randomized comparator. Its ORR confidence interval was 43.4% to 87.4%, and the PFS upper confidence limit was not estimable. These results do not establish a comparative survival benefit. The study-wide safety percentage is not an EGFR-cohort-specific estimate.

MARIPOSA-2

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Median progression-free survival
Amivantamab plus chemotherapy, monthsAmivantamab plus lazertinib and chemotherapy, monthsChemotherapy, months
“6.3”View highlighted excerpt for this quote“8.3”View highlighted excerpt for this quote“4.2”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This trial compares amivantamab-based combinations with chemotherapy, not with ivonescimab. Its PFS results therefore cannot establish the relative efficacy of amivantamab and ivonescimab. Toxicities span hematologic, EGFR-related, and MET-related categories; a PFS comparison alone does not summarize the full benefit-risk balance.

KEYNOTE-789

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants by group
Description of analysis sets
Prespecified efficacy threshold and PFS test
Statistical quantityQuoted value
One-sided efficacy boundary for PFS and OS“.0117”View highlighted excerpt for this quote
Observed one-sided PFS P value“.0122”View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Grade 3 or higher treatment-related adverse events
Study limitations
Summary

The PFS P value of 0.0122 did not meet the prespecified one-sided boundary of 0.0117. Neither primary efficacy endpoint was met. These results concern pembrolizumab plus chemotherapy, not ivonescimab, and cannot determine the effect of simultaneous PD-1 and VEGF inhibition.

CheckMate 722

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and randomized participants
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Median progression-free survival
Health-related quality of life and patient-reported outcomes
Safety results
Grade 3 or 4 treatment-related adverse events
Study limitations
Summary

The enrollment target was reduced from 500 to 270 participants, and the estimated power with observed PFS events was 76%. The open-label study did not meet its primary PFS endpoint. Grade 3 or 4 TRAEs were reported in 44.7% versus 29.4%. The trial evaluates nivolumab, not ivonescimab.

COMPEL

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Median survival outcomes
OutcomeOsimertinib plus chemotherapy, monthsPlacebo plus chemotherapy, months
PFS“8.4”“4.4”
OS“15.9”“9.8”
Overall survival hazard ratio: 95% confidence interval
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Grade 3 or higher adverse events
Osimertinib plus chemotherapyPlacebo plus chemotherapy
“63%”“46%”
Study limitations
Summary

There were 49 participants per arm, and eligibility required non-CNS progression. The OS hazard-ratio confidence interval included 1, so the numerical median OS difference does not establish an OS benefit. This study does not directly compare osimertinib continuation with ivonescimab.

TROPION-Lung05

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using objective response rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study-wide safety outcomes
Safety outcomeQuoted percentage
Grade 3 or higher treatment-related adverse events“28.5%”View highlighted excerpt for this quote
Adjudicated treatment-related interstitial lung disease or pneumonitis“3.6%”View highlighted excerpt for this quote
Grade 5 interstitial lung disease or pneumonitis“0.7%”View highlighted excerpt for this quote
Study limitations
Summary

The 137-participant population included multiple genomic subgroups; 56.9% had EGFR mutations. The overall ORR and safety percentages should not be presented as EGFR-specific estimates. The EGFR-subgroup ORR of 43.6% is not a randomized comparison with ivonescimab.

Case report: malignant pleural effusion and acquired complex resistance

Objective
Location and study date
Study design
Eligibility criteria

Not applicable.

Treatment
Study outcomes
Rationale for using radiographic disease control as the reported outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)

Not applicable.

Description of analysis sets

Not applicable.

Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

This single-participant case cannot estimate a comparative treatment effect or establish that the reported resistance pattern predicts benefit. Disease control during monotherapy and subsequent combination treatment should not be conflated. The qualitative safety description does not provide an adverse-event rate.

Case report: lung adenosquamous carcinoma after multiline therapy

Objective
Location and study date
Study design
Eligibility criteria

Not applicable.

Treatment
Study outcomes
Rationale for using radiographic partial response as the reported outcome

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)

Not applicable.

Description of analysis sets

Not applicable.

Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The report describes one participant with adenosquamous histology and multiple previous therapies. A response sustained over six cycles cannot establish an OS benefit, comparative efficacy, or the frequency of uncommon toxicity. The findings should not be generalized to all EGFR-mutated NSCLC.

HARMONi-5

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using objective response rate as a primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study-wide treatment-related adverse events
OutcomeQuoted percentage
Grade 3 or higher TRAEs“22.2%”View highlighted excerpt for this quote
TRAEs leading to death, reported in squamous NSCLC“2.8%”View highlighted excerpt for this quote
Study limitations
Summary

This phase 1b evidence concerns monotherapy, not the chemotherapy combination evaluated in the pivotal trials. Grade 3 or higher TRAEs occurred in 22.2%, and TRAEs leading to death were reported in 2.8%. The monotherapy response estimate should not be substituted for post-TKI combination-treatment efficacy.

AK112-101

Objective
Location and study date
Enrollment dates reported in the publication
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Efficacy results
Antitumor activity among response-evaluable participants
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

The study enrolled 51 participants with advanced solid tumors, with 47 contributing a postbaseline response assessment. Descriptive dose-escalation findings do not establish efficacy specifically in EGFR-mutated NSCLC. The publication gives different enrollment end dates in its abstract and results section; neither date has been silently substituted for the other. The maximum tolerated dose is specific to this study and schedule.

AK112-102

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Planned and treated participants
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Representation of non-small-cell lung cancer
Baseline characteristicQuoted count and percentage
Participants with non-small-cell lung cancer, n (%)“1 (1.7)”View highlighted excerpt for this quote
Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-related adverse events
Study limitations
Summary

Only 1 of 59 participants, 1.7%, had NSCLC. These descriptive safety and pharmacology findings cannot establish efficacy for EGFR-mutated NSCLC. Unlike the Australian phase 1a study, this study did not reach a maximum tolerated dose; the results should not be merged into a single universal maximum-dose conclusion.